UN OWG Proposed Target 3b

For R&D into vaccines and medicines the rating is PHENOMENAL – there are considerable costs to undertake this research but the benefits are enormous. For the rest of the target the rating is FAIR – pharmaceutical companies have provided concessional price access for diseases in developing countries (e.g. HIV) which are not as prevalent as in the developed world. Additionally, pharmaceutical companies have not been readily willing to commit to patent pools. In the absence of pharmaceutical cooperation, large costly mechanisms are required to improve affordability for developing world individuals, which can be difficult to finance. The benefit-cost profile depends on the disease and treatment in question. Subsidizing combination treatments of artemisinin for malaria via the “Affordable Medicines Facility” for example has a PHENOMENAL benefit to cost ratio (Jamison et al, 2012).
Download the entire report
In our recent report, not just the target above, but all 169 targets have been assessed by 60 teams of the world’s top economists. The targets have been categorized into five ratings based on evidence of economic, social, and environmental costs and benefits. While we applaud that the UN Open Working Group's final outcome document contains 43 fewer targets than the previous document, we are concerned that many targets have simply been combined, therefore reducing the number of both phenomenal and poor targets assessed according to our cost-benefit analysis. Our new assessment includes suggestions for how these can be improved as reported in this article by the Financial Times.